Advanced Genomics Tools Will Shape Future Precision Medicine

AN

AnalystConsensusTarget

AnalystConsensusTarget

Not Invested

Based on Analyst Price Targets

Published

23 Mar 25

Updated

27 Nov 25

n/a

n/a

AnalystConsensusTarget's Fair Value

n/a

1Y

12.0%

7D

-5.5%

Loading

1Y

12.0%

7D

-5.5%

You can edit this narrative until Nov 28 7:05 AM. Then, changes will post as Updates.

Author's Valuation

US$16.368.6% overvalued

AnalystConsensusTarget Fair Value

Shared on 27 Nov 25

Fair value Increased 3.15%

TXG: ARK Share Purchase Will Not Offset Persistent Market Pressure

Analysts have modestly raised their fair value estimate for 10x Genomics from $15.86 to $16.36 per share. This change reflects expectations of improved revenue growth, a resilient market position, and support from recent institutional investment activity, despite ongoing macroeconomic headwinds.

Shared on 09 Nov 25

Fair value Increased 5.17%

TXG: Institutional Interest And New Assay Expected To Influence Future Performance

Analysts have increased their price target for 10x Genomics from $15.08 to $15.86 per share. They cite improvements in revenue growth and profit margin as key factors behind the upward revision.

Shared on 08 Aug 25

Fair value Increased 11%

Despite a decline in consensus revenue growth forecasts, a rising future P/E suggests increased optimism for profitability or valuation, leading to a higher analyst price target for 10x Genomics. What's in the News 10x Genomics guided Q3 2025 revenue to $140–$144 million, noting an impact from $4.0 million in China customer purchases pulled forward due to anticipated tariff changes.

Shared on 01 May 25

Fair value Decreased 12%

Shared on 24 Apr 25

Fair value Decreased 1.02%

AnalystConsensusTarget made no meaningful changes to valuation assumptions.

Shared on 17 Apr 25

Fair value Decreased 3.34%

AnalystConsensusTarget made no meaningful changes to valuation assumptions.

Shared on 09 Apr 25

Fair value Decreased 2.12%

AnalystConsensusTarget made no meaningful changes to valuation assumptions.

Shared on 02 Apr 25

Fair value Increased 1.60%

AnalystConsensusTarget made no meaningful changes to valuation assumptions.

Shared on 26 Mar 25

Fair value Increased 24%

AnalystConsensusTarget made no meaningful changes to valuation assumptions.

AnalystConsensusTarget Fair Value

US$16.36

8.6% overvalued

Future estimation in

% p.a.

0

Decrease

Increase

Current revenue growth rate

3.09%

Life Sciences revenue growth rate

0.27%

Risk Level (Discount Rate)

Our default considers factors like the company's size, volatility, profitablity and country of operation.

%

0

Decrease

Increase

Current discount rate

7.81%

Calculation

US$109.40m

Earnings '28

x

26.25x

PE Ratio '28

=

US$2.87b

Market Cap '28

US$2.87b

Market Cap '28

/

140.21m

No. shares '28

=

US$20.48

Share Price '28

US$20.48 Share Price '28

Discounted to 2025 @ 7.83% p.a.

=

US$16.33

Fair Value '25